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Renal hypoxia with loss of microvasculature plays a
key role in progression of renal disease. Recently, admin-
istration of erythropoietin (EPO) in chronic renal failure
patients has been reported to result in better renal sur-
vival with a correction of anemia. The mechanisms of
the beneficial effect of EPO on patients’ survival may be
related to an increased oxygen delivery to tissues and re-
duction of hypoxia with anemia correction or any other
direct effect of EPO. In order to examine the renoprotec-
tive effect of EPO with potential mechanisms, we admin-
istered subcutaneous recombinant human EPO (rhEPO)
(Darbepoietin) (0.4 lg/kg/week) into 5/6 remnant kidney
(RK) rats after renal mass reduction, and sacrificed the
rats at 1, 2, and 12 weeks of EPO administration. RK +
EPO rats showed a higher hematocrit from 4 weeks after
EPO compared to RK + vehicle rats. EPO treatment in
RK rats was associated with better preservation of renal
function at 12 weeks after renal mass reduction (serum
creatinine 2.6 ± 0.6 vs. 1.5 ± 0.5 mg/dL, RK vs. RK +
EPO) (P < 0.05) with less renal scarring. Microvascular
density and endothelial cell proliferation in glomerulus
and tubulointerstitium were significantly higher in RK +
EPO rats compared to RK + vehicle rats. Renal cortical
expression of vascular endothelial growth factor (VEGF)
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expression at 12 weeks was also higher in RK + EPO rats.
In vitro experiment with renal tubular cells [NRK52E and
medullary thick ascending limb of Henle (mTAL) cells]
showed a proliferative response with EPO (0.1 to 100
U/mL) with an up-regulation of VEGF expression. EPO
also prevented hypoxia-induced apoptosis of mTAL cells.
In conclusion, EPO treatment in animal model of
chronic renal failure was associated with better preser-
vation of renal function and structure. Possible mech-
anisms for this renoprotective effect of EPO may be
related to amelioration of renal hypoxia not only by cor-
recting anemia but also by enhancing renal microvascu-
lar cell survival and/or angiogenesis. Direct prosurvival
effect of EPO on renal tubular cell with up-regulation of
VEGF expression can be also an important mechanism
of this renoprotective effect of EPO.
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